123 related articles for article (PubMed ID: 7833124)
1. Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide.
Scherübl H; Wiedenmann B; Riecken EO; Thomas F; Böhme E; Räth U
Eur J Cancer; 1994; 30A(10):1590-1. PubMed ID: 7833124
[No Abstract] [Full Text] [Related]
2. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.
Ruszniewski P; Valle JW; Lombard-Bohas C; Cuthbertson DJ; Perros P; Holubec L; Delle Fave G; Smith D; Niccoli P; Maisonobe P; Atlan P; Caplin ME;
Dig Liver Dis; 2016 May; 48(5):552-558. PubMed ID: 26917486
[TBL] [Abstract][Full Text] [Related]
3. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
[TBL] [Abstract][Full Text] [Related]
4. Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors.
Wolin EM; Manon A; Chassaing C; Lewis A; Bertocchi L; Richard J; Phan AT
J Gastrointest Cancer; 2016 Dec; 47(4):366-374. PubMed ID: 27619395
[TBL] [Abstract][Full Text] [Related]
5. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.
Ducreux M; Ruszniewski P; Chayvialle JA; Blumberg J; Cloarec D; Michel H; Raymond JM; Dupas JL; Gouerou H; Jian R; Genestin E; Hammel P; Rougier P
Am J Gastroenterol; 2000 Nov; 95(11):3276-81. PubMed ID: 11095353
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel).
Khan MS; El-Khouly F; Davies P; Toumpanakis C; Caplin ME
Aliment Pharmacol Ther; 2011 Jul; 34(2):235-42. PubMed ID: 21585408
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin Analogues in Neuroendocrine Tumors.
Kulke MH
J Natl Compr Canc Netw; 2016 Mar; 14(3):241-2. PubMed ID: 26957610
[No Abstract] [Full Text] [Related]
8. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria.
Rinke A; Maintz C; Müller L; Weber MM; Lahner H; Pavel M; Saeger W; Houchard A; Ungewiss H; Petersenn S
Exp Clin Endocrinol Diabetes; 2021 Jul; 129(7):500-509. PubMed ID: 34293802
[TBL] [Abstract][Full Text] [Related]
9. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Guadalupe E; Deshpande HA; Stein SM
Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
[TBL] [Abstract][Full Text] [Related]
10. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide.
Ruszniewski P; Ish-Shalom S; Wymenga M; O'Toole D; Arnold R; Tomassetti P; Bax N; Caplin M; Eriksson B; Glaser B; Ducreux M; Lombard-Bohas C; de Herder WW; Delle Fave G; Reed N; Seitz JF; Van Cutsem E; Grossman A; Rougier P; Schmidt W; Wiedenmann B
Neuroendocrinology; 2004; 80(4):244-51. PubMed ID: 15627802
[TBL] [Abstract][Full Text] [Related]
11. Regression of liver metastases of occult carcinoid tumor with slow release lanreotide therapy.
Bondanelli M; Ambrosio MR; Zatelli MC; Cavazzini L; Al Jandali Rifa'y L; degli Uberti EC
World J Gastroenterol; 2005 Apr; 11(13):2041-4. PubMed ID: 15801004
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers.
Antonijoan RM; Barbanoj MJ; Cordero JA; Peraire C; Obach R; Vallès J; Chérif-Cheikh R; Torres ML; Bismuth F; Montes M
J Pharm Pharmacol; 2004 Apr; 56(4):471-6. PubMed ID: 15099442
[TBL] [Abstract][Full Text] [Related]
13. Long-acting formulations of somatostatin analogues.
Anthony LB
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S216-8. PubMed ID: 10604134
[TBL] [Abstract][Full Text] [Related]
14. Gluteal nodules in patients with metastatic midgut carcinoid disease treated with depot somatostatin analogs.
Debono M; Hon LQ; Bax N; Blakeborough A; Newell-Price J
J Clin Endocrinol Metab; 2008 May; 93(5):1860-4. PubMed ID: 18303072
[TBL] [Abstract][Full Text] [Related]
15. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.
Kvols LK; Moertel CG; O'Connell MJ; Schutt AJ; Rubin J; Hahn RG
N Engl J Med; 1986 Sep; 315(11):663-6. PubMed ID: 2427948
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.
Ryan P; Phan AT; Adelman DT; Iwasaki M
Clin J Oncol Nurs; 2016 Dec; 20(6):E139-E146. PubMed ID: 27857269
[TBL] [Abstract][Full Text] [Related]
17. Role of lanreotide in an elderly patient with Merkel cell carcinoma.
Ghidini A; Petrelli F; Fazio I; Santangelo D
Dermatol Ther; 2020 Jan; 33(1):e13206. PubMed ID: 31886588
[No Abstract] [Full Text] [Related]
18. Successful symptomatic treatment of malignant carcinoid syndrome with the somatostatin analogue SMS 201-995.
van Houten AA; Nortier JW; Vendrik CP
Neth J Med; 1988 Apr; 32(3-4):194-8. PubMed ID: 2896307
[No Abstract] [Full Text] [Related]
19. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.
Wymenga AN; Eriksson B; Salmela PI; Jacobsen MB; Van Cutsem EJ; Fiasse RH; Välimäki MJ; Renstrup J; de Vries EG; Oberg KE
J Clin Oncol; 1999 Apr; 17(4):1111. PubMed ID: 10561168
[TBL] [Abstract][Full Text] [Related]
20. The safety of lanreotide for neuroendocrine tumor.
Godara A; Siddiqui NS; Byrne MM; Saif MW
Expert Opin Drug Saf; 2019 Jan; 18(1):1-10. PubMed ID: 30582380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
